Related Experiment Video
Updated: Aug 29, 2025
Assessing Functional Performance in the Mdx Mouse Model
Published on: March 27, 2014
Pharmacological TRPC6 inhibition improves survival and muscle function in mice with Duchenne muscular dystrophy
Brian L Lin1, Joseph Y Shin1, William Pd Jeffreys1
1Department of Cardiology.
Abstract:
Gene mutations causing loss of dystrophin result in the severe muscle disease known as Duchenne muscular dystrophy (DMD). Despite efforts at genetic repair, DMD therapy remains largely palliative. Loss of dystrophin destabilizes the sarcolemmal membrane, inducing mechanosensitive cation channels to increase calcium entry and promote cell damage and, eventually, muscle dysfunction. One putative channel is transient receptor potential canonical 6 (TRPC6); we have shown that TRPC6 contributed to abnormal force and calcium stress-responses in cardiomyocytes from mice lacking dystrophin that were haplodeficient for utrophin (mdx/utrn+/- [HET] mice). Here, we show in both the HET mouse and the far more severe homozygous mdx/utrn-/- mouse that TRPC6 gene deletion or its selective pharmacologic inhibition (by BI 749327) prolonged survival 2- to 3-fold, improving skeletal and cardiac muscle and bone defects. Gene pathways reduced by BI 749327 treatment most prominently regulated fat metabolism and TGF-β1 signaling. These results support the testing of TRPC6 inhibitors in human trials for other diseases as a novel DMD therapy.
Insights
Targeting the TRPC6 channel significantly improved survival and muscle function in Duchenne muscular dystrophy (DMD) mouse models. TRPC6 inhibition offers a promising therapeutic strategy for this severe genetic muscle disease.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Duchenne muscular dystrophy (DMD) is a severe genetic muscle disease caused by dystrophin loss.
- Current DMD therapies are largely palliative, highlighting the need for novel treatment strategies.
- Dystrophin deficiency destabilizes muscle cell membranes, leading to increased calcium influx via channels like TRPC6, causing cell damage and dysfunction.
Purpose of the Study:
- To investigate the role of Transient Receptor Potential Canonical 6 (TRPC6) in DMD pathophysiology.
- To evaluate the therapeutic potential of TRPC6 inhibition in preclinical DMD models.
Main Methods:
- Utilized dystrophin-deficient mouse models (mdx/utrn+/- and mdx/utrn-/-).
- Assessed the effects of TRPC6 gene deletion and pharmacologic inhibition (BI 749327) on survival and muscle function.
- Analyzed gene expression pathways affected by TRPC6 inhibition.
Main Results:
- TRPC6 inhibition (gene deletion or BI 749327) increased survival 2- to 3-fold in DMD mouse models.
- Pharmacologic TRPC6 inhibition improved skeletal muscle, cardiac muscle, and bone defects.
- BI 749327 treatment modulated gene pathways involved in fat metabolism and TGF-β1 signaling.
Conclusions:
- TRPC6 plays a significant role in DMD progression and pathology.
- TRPC6 inhibition represents a promising novel therapeutic approach for Duchenne muscular dystrophy.
- Further investigation and human trials of TRPC6 inhibitors are warranted for DMD and potentially other diseases.
More Related Videos
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...